A Gram-Daily Aldehyde for Anemia: Voxelotor - Drug Hunter
VOXELOTOR | New Drug Approvals
Oxbryta (voxelotor) - Rare Disease Advisor
Therapeutic strategies for sickle cell disease: towards a multi-agent approach | Nature Reviews Drug Discovery
IJNS | Free Full-Text | Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment | HTML
An Integrated Research On Global Blood Therapeutics: Is Voxelotor The Answer For Sickle Cell Disease? (NASDAQ:GBT) | Seeking Alpha
Voxelotor - Wikipedia
Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials - Experimental Hematology
l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope? - ScienceDirect
Frontiers | Recent Advances in the Treatment of Sickle Cell Disease | Physiology
Molecules | Free Full-Text | Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease | HTML
Targeting sickle cell disease root-cause pathophysiology with small molecules | Haematologica
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Haematology
Oxbryta® (voxelotor) tablets Mechanism of Action
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease | NEJM
Daily Medication Pearl: Voxelotor (Oxbryta)
Oxbryta® (voxelotor) tablets Mechanism of Action
Therapeutic Advances in Hematology on Twitter: "Current and novel therapies for the prevention of vaso-occlusive crisis in #SickleCell disease. Check out this #openaccess review, from Ifeyinwa Osunkwo, Deepa Manwani and Julie Kanter @
The molecular basis for the prothrombotic state in sickle cell disease | Haematologica
Oxbryta® (voxelotor) tablets Mechanism of Action
Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease
Oxbryta® (voxelotor) tablets Mechanism of Action
10-K
